Cidara Therapeutics (CDTX) skyrocketed 105% on news of a $9.2 billion acquisition bid from Merck. Shares hit $218.85 before closing at $217.71. The deal is set to close in Q1 2026. CDTX also received FDA fast track designation for its flu prevention drug, CD388, currently in Phase 3 trials.

Read more at Yahoo Finance: Cidara Therapeutics (CDTX) Skyrockets 105% on Merck $9.2-Billion Acquisition Bid